Rapid Japan review sets stage for Xeljanz's second approval worldwide
This article was originally published in Scrip
In a move that clears the way to only its second approval worldwide, Japan has given a positive opinion to Pfizer's novel rheumatoid arthritis (RA) drug Xeljanz (tofacitinib citrate).
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.